



Cancer Stem Cells in Major Smoking Related Cancers

Guest Editors:

Dr. Mohammad O. Hoque

Department of Otolaryngology-
Head and Neck Surgery, Johns
Hopkins University School of
Medicine, Baltimore, MD 21231,
USA

Dr. Pritam Sadhukhan

Department of Otolaryngology,
Head and Neck Surgery, Johns
Hopkins University School of
Medicine, Baltimore, MD 21231,
USA

Deadline for manuscript
submissions:

closed (30 December 2024)

Message from the Guest Editors

Therapeutic resistance remains a significant hurdle in treating patients with different types of cancer, including lung cancer, bladder cancer, and head and neck cancer. These three cancer types are closely associated with active and/or passive smoking. The chemicals present in tobacco smoke can cause DNA damage that enhances genetic and epigenetic alterations at the cellular level, eventually leading to the development of neoplastic changes. The risk of other cancer types, such as esophageal cancer, pancreatic cancers, kidney cancer, and cervical cancer, is also known to be increased due to smoking exposure. Numerous environmental exposures (such as smoking) have been reported to be associated with inducing different molecular alterations, initiating and promoting cancer stem cells (CSCs), and ultimately contributing to therapeutic resistance. It is important to note that the relationship between smoking and cancer stem cells is complex and multifactorial, and more research is needed to fully understand the underlying mechanisms. This SI aims to highlight recent advancements in CSC research associated with therapeutic resistance that could improve cancer management and treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)